Azar Alex M II sold $10K of GH
Azar Alex M II sold 69 shares of Guardant Health, Inc. (GH) at $149.56 on 2026-11-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Because the transaction is a small open-market sale and explicitly pre-arranged, it typically does not warrant a fundamental repricing. The main trading relevance is sentiment monitoring for unusual clustering of insider sales.
Market read
Routine insider selling disclosure with limited expected price impact.
What to watch
The article does not disclose any buy-side offset, broader insider activity, or changes in operating outlook, limiting the signal beyond routine compliance.
Background
The article is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc., reported by a director under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Guardant Health director Azar Alex M II filed a Form 4 showing an open-market sale of 69 shares at $149.56 on 2026-11-16 under a 10b5-1 plan.
Likely limited impact; any reaction would be muted because the transaction is small and explicitly under a Rule 10b5-1 plan.
The filing is a Form 4 insider transaction, not an earnings, guidance, or regulatory event. The article provides only a modest sale size and confirms it is pre-arranged via 10b5-1, which typically reduces interpretive signal.
Market effects
No clear sector read-through; this is company-specific insider trading with no operational or regulatory catalyst.
None.
None.
Counterpoint
Even 10b5-1 sales can coincide with periods of insider risk management, so traders may briefly watch for follow-on selling or other insider activity.
Key entities
- issuerGuardant Health, Inc.
US-listed company subject of the Form 4 insider transaction disclosure.
- insiderAzar Alex M II
Director who sold 69 shares on 2026-11-16 under a Rule 10b5-1 plan.

